Published in Therap Adv Gastroenterol on September 01, 2012
Enterococcus gallinarum Spontaneous Bacterial Peritonitis in an HCV Cirrhotic. Case Reports Hepatol (2015) 0.75
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Management of adult patients with ascites due to cirrhosis: an update. Hepatology (2009) 5.26
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol (2010) 4.55
Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol (2000) 3.43
Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis (2001) 2.76
Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA (2008) 2.69
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol (1999) 1.82
Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology (2006) 1.71
Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol (2001) 1.37
Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology (1986) 1.30
Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol (2008) 1.26
Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointestin Liver Dis (2006) 1.15
Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg (1986) 1.13
Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol (1993) 1.04
Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol (2009) 1.01
Bacteremia is a prognostic factor for poor outcome in spontaneous bacterial peritonitis. Scand J Infect Dis (2007) 1.00
In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. Eur J Gastroenterol Hepatol (2008) 0.96
Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis. J Gastroenterol Hepatol (2001) 0.96
Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. J Gastroenterol Hepatol (2009) 0.95
Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology (1989) 0.87
Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study. Eur J Clin Microbiol Infect Dis (2006) 0.87
The value of ascitic fluid polymorphonuclear cell count determination during therapy of spontaneous bacterial peritonitis in patients with liver cirrhosis. Hepatogastroenterology (2001) 0.86
Usefulness of reagent strips for checking cure in spontaneous bacterial peritonitis after short-course treatment. Aliment Pharmacol Ther (2010) 0.86
Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol (2008) 0.86
Association between model for end-stage liver disease and spontaneous bacterial peritonitis. Am J Gastroenterol (2007) 0.84
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol (2009) 1.86
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (2012) 1.76
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol (2012) 1.68
Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl (2003) 1.64
Impact of experience with a retrograde-viewing device on adenoma detection rates and withdrawal times during colonoscopy: the Third Eye Retroscope study group. Gastrointest Endosc (2010) 1.59
Colonic perforation during screening CT colonography using automated CO2 insufflation in an asymptomatic adult. Abdom Imaging (2008) 1.53
A case of adult hepatic toxocariasis. Nat Clin Pract Gastroenterol Hepatol (2008) 1.51
Advances in ambulatory monitoring: regulatory considerations. J Electrocardiol (2004) 1.39
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology (2013) 1.38
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology (2013) 1.26
Operative risk of total hip and knee arthroplasty in cirrhotic patients. J Arthroplasty (2005) 1.15
Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int (2013) 1.13
Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease. Surg Infect (Larchmt) (2009) 1.10
Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS (2004) 1.06
Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause (2004) 1.05
Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. Hepatology (2013) 1.04
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology (2012) 1.03
Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol (2008) 0.96
Multiphasic analysis of the temporal development of the distal gut microbiota in patients following ileal pouch anal anastomosis. Microbiome (2013) 0.96
Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology (2014) 0.96
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol (2010) 0.94
Epstein-barr virus: an unusual cause of cholestatic hepatitis in older adults. Gastroenterol Hepatol (N Y) (2007) 0.92
The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl (2003) 0.91
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl (2006) 0.88
Herbal hepatoxicity from Chinese skullcap: A case report. World J Hepatol (2012) 0.88
Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology (2012) 0.87
The safety and outcome of joint replacement surgery in liver transplant recipients. Liver Transpl (2003) 0.87
Peliosis hepatis in a living related liver transplantation donor candidate. J Gastroenterol Hepatol (2006) 0.86
Distributive justice and the arrival of direct-acting antivirals: who should be first in line? Hepatology (2011) 0.86
Liver disease in pregnancy. Clin Liver Dis (2012) 0.84
A case of biliopleural fistula in a patient with hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 0.84
Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation (2012) 0.82
Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol (2009) 0.82
Co-management between hospitalist and hepatologist improves the quality of care of inpatients with chronic liver disease. J Clin Gastroenterol (2014) 0.82
Is the HCV pipeline heading in the right direction? Gastroenterology (2013) 0.82
Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl (2002) 0.82
CT colonography of a Medicare-aged population: outcomes observed in an analysis of more than 1400 patients. AJR Am J Roentgenol (2012) 0.81
Hepatobiliary manifestations of critically ill and postoperative patients. Clin Liver Dis (2011) 0.79
Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep (2013) 0.79
Multiphase Multi-Detector Row Computed Tomography Imaging Characteristics of Large (>5 cm) Focal Hepatocellular Carcinoma. J Comput Assist Tomogr (2016) 0.78
Dobutamine stress echocardiography in patients undergoing orthotopic liver transplantation: a pooled analysis of accuracy, perioperative and long term cardiovascular prognosis. Int J Cardiovasc Imaging (2013) 0.78
Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant (2002) 0.77
Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant (2012) 0.76
Multiple progressive focal nodular hyperplasia lesions of liver in a patient with hemosiderosis. World J Radiol (2010) 0.75
Management of hepatitis B virus. J Antimicrob Chemother (2008) 0.75
Liver Transplantation in the Obese Cirrhotic Patient. Transplantation (2017) 0.75
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Dig Dis Sci (2013) 0.75
Paraesophageal hernia: a rare presentation of Marfan syndrome in adults. Gastrointest Endosc (2007) 0.75
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol (2016) 0.75
Use of standards in the review of medical devices. J Electrocardiol (2005) 0.75
Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis (2011) 0.75
Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol (2017) 0.75
Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology (2013) 0.75